Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...
This guide was reviewed by a Business News Daily editor to ensure it provides comprehensive and accurate information to aid your buying decision. Modern businesses run on data. Companies regularly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback